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Upon recognition of antigen, B cells undergo rapid proliferation followed by differentiation
to specialized antibody secreting cells (ASCs). During this transition, B cells are reliant
upon a multilayer transcription factor network to achieve a dramatic remodeling of the
B cell transcriptional landscape. Increased levels of ASCs are often seen in autoimmune
diseases and it is believed that altered expression of regulatory transcription factors play
a role in this imbalance. The transcription factor interferon regulatory factor 5 (IRF5) is one
such candidate as polymorphisms in IRF5 associate with risk of numerous autoimmune
diseases and correlate with elevated IRF5 expression. IRF5 genetic risk has been widely
replicated in systemic lupus erythematosus (SLE), and loss of Irf5 ameliorates disease
in murine lupus models, in part, through the lack of pathogenic autoantibody secretion.
It remains unclear, however, whether IRF5 is contributing to autoantibody production
through a B cell-intrinsic function. To date, IRF5 function in healthy human B cells has not
been characterized. Using human primary naive B cells, we define a critical intrinsic role
for IRF5 in B cell activation, proliferation, and plasmablast differentiation. Targeted IRF5
knockdown resulted in significant immunoglobulin (Ig) D retention, reduced proliferation,
plasmablast differentiation, and IgG secretion. The observed decreases were due to
impaired B cell activation and clonal expansion. Distinct from murine studies, we identify
and confirm new IRF5 target genes, IRF4, ERK1, and MYC, and pathways that mediate
IRF5 B cell-intrinsic function. Together, these results identify IRF5 as an early regulator
of human B cell activation and provide the first dataset in human primary B cells to map
IRF5 dysfunction in SLE.
Keywords: interferon regulatory factor 5, human primary B cells, plasmablasts, autoantibodies, immunoglobulin
G, differentiation, toll-like receptor

INTRODUCTION
Antibody secreting cells (ASCs), referred to as plasmablasts and plasma cells, are critical mediators
of adaptive immunity and are often found elevated in the circulation of patients with systemic lupus
erythematosus (SLE) (1–4). ASCs release high titers of antibody capable of neutralizing invading antigen and stem from naive and memory B cells that have been activated through antigen
recognition. Differentiation of naive B cells to ASCs requires multiple B cell activation pathways,
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including B cell receptor (BCR), T cell-mediated cytokine signaling, and toll-like receptors (TLRs) (5, 6). BCR activation occurs
through binding of cognate antigen, leading to activation of
distal signaling cascades, including the Ras-Raf-MEK-ERK1/2
kinase cascade and the Btk-PI3K-PLC-NFĸB cascade, ultimately
culminating in transcriptional activation of proliferation and
prosurvival genes (7, 8). Complimentary T cell activation
allows for interaction between B and T cells. Engagement of
the respective B and T cell surface proteins, CD40 and CD40
ligand (CD40L), further enhances transcription of B cell survival
and proliferation genes. T cell-mediated cytokine signaling acts
to drive ASC differentiation, as well as to specify the antibody
subclass secreted. TLR signaling can act synergistically with both
T cell-dependent and -independent B cell activation pathways
and represents a unique bridge between innate and adaptive
immune responses (9).
These various B cell activation pathways utilize a network
of transcription factors to drive proliferation, survival and differentiation (3). Immediately following activation, B cells rapidly
proliferate to ensure sufficient numbers of antigen-specific B cells
to undergo ASC differentiation. This initial burst of proliferation
is dependent on the transcription factor MYC (10, 11). Following
several rounds of proliferation, B cells upregulate interferon
regulatory factor 4 (IRF4), BLIMP1, and XBP1, which control
ASC differentiation and prepare the cell for antibody secretion
(3, 12–14). In response to IRF4 upregulation, B cells undergo
terminal chromosomal rearrangement of the immunoglobulin
(Ig) locus known as class switch recombination (CSR) (12). CSR
results in the switching of antibody subtype from IgM to IgG,
IgA, or IgE, and is dependent on the enzyme activation-induced
deaminase (AID). The majority of work on ASC differentiation
has occurred in mice as human primary B cells are notoriously
difficult to manipulate (by knockdown or overexpression) for
functional analyses.
Genetic variants in or near the transcription factor interferon
regulatory factor 5 (IRF5) have been robustly associated with
SLE risk and elevated IRF5 expression and activation have been
reported in SLE immune cells (15–19). Mice lacking Irf5 are
protected from murine lupus disease onset and severity (20–23).
A common finding between the different models of murine lupus
that lack Irf5 is the significant decrease in pathogenic autoantibody secretion suggesting a role for IRF5 in B cells. In mice,
Irf5 was found to regulate IL6, PRDM1, and IgG2a expression
(22, 24–26). SLE pathogenesis is associated with polyclonal B cell
hyperreactivity resulting in an autoreactive B cell repertoire,
elevated circulating ASCs and autoantibodies (2, 27). Whether
IRF5 contributes to ASC differentiation or antibody production
in human primary B cells is not known.
Here, we developed a method of targeted gene knockdown in
human primary naive B cells. While IRF5 expression and activity
have been well-characterized in human monocytes and dendritic
cells, its role in B cells remains to be defined (19, 28–35). We
show that IRF5 is required in the early stages of B cell activation and proliferation in response to TLR9/BCR-induced ASC
differentiation. IRF5 knockdown resulted in a significant increase
in the number of IgD+ B cells, reduced activation, clonal expansion, plasmablast differentiation, and IgG1/3 secretion. Distinct
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from murine studies, we identify and confirm new IRF5 target
genes, IRF4, ERK1, and MYC, that mediate IRF5 B cell-intrinsic
function.

MATERIALS AND METHODS
Naive B Cell Isolation

Blood was drawn via peripheral phlebotomy and PBMC
isolated by Ficoll centrifugation (18). PBMC were diluted to
a concentration of 5 × 107 cells/mL and naive B cells isolated
using Stem Cell Technologies Kit (Cat#: 19254). Magnetic separation was performed to achieve a >95% enriched population of
naive B cells (CD19+CD20+IgD+CD27−), as determined by flow
cytometry (Figure S1A in Supplementary Material). This study
was carried out in accordance with the recommendations of the
Rutgers Biomedical and Health Sciences IRB and the Feinstein
Institute for Medical Research IRB with written informed
consent from all subjects. All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The
protocol was approved by the Rutgers Biomedical and Health
Sciences IRB and the Feinstein Institute for Medical Research
IRB. The Ramos lymphoblastic B cell line was purchased from
ATCC® and cultured in RPMI-1640 with 10% fetal bovine
serum.

Imaging Flow Cytometry Analysis
of IRF5 Activation

Isolated PBMC were stained for CD19 (BD Biosciences #562847)
and fixed overnight in 1% paraformaldehyde. Cells were permeabilized the following day in 0.01% Triton-X-100 and stained for
intracellular IRF5 (Abcam #ab193245) (19). Images were acquired
on the Amnis ImageStream X Mark II imaging flow cytometer
using the 40× objective. Nuclear translocation was quantified in
the Amnis IDEAS software suite using the similarity score feature
(Figure S1B in Supplementary Material).

IRF5 siRNA Nucleofection

Isolated naive B cells (3 × 106) were resuspended in Amaxa
buffer P3 (Lonza: #V4XP-3032) and distributed to Amaxa
100 µL cuvettes. B cells were nucleofected with 500 nM of mock,
ON-TARGETplus non-targeting control pool (GE Dharmacon:
#D-001810-10-05), or SMARTpool ON-TARGETplus human
IRF5 siRNA (GE Dharmacon: #L-011706-00-0010). Cells were
nucleofected on the Amaxa 4D Nucleofector using program
EO-117 and then immediately added to 1 mL of RPMI 1640
(+10% FBS, 1× glutamine, 1× non-essential amino acids) and
cultured for 24 h, pelleted and re-nucleofected with siRNA. For
GFP co-nucleofection, pmaxGFP™ Vector (Lonza) or GFP
mRNA (Trinity Biotech: #L6101) was titrated over a concentration range with 500 nM IRF5 siRNA; 15 µg GFP mRNA gave the
best results.

qRT-PCR and Western Blotting

RNA was isolated with Trizol® and qRT-PCR performed as
described (18) with primer sets: MYC 5′-CCTGGTGCTCCATG
AGGAGAC, 3′-CAGACTCTGACCTTTTGCCAGG; IRF4 5′-G
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stimulated for 5 days. Proliferation was analyzed in Live/
Dead−CD19+CD20+CD38lo B cells.

AACGAGGAGAAGAGCATCTTCC, 3′-CGATGCCTTCTCGG
AACTTTCC; IL6 5′-AGACAGCCACTCACCTCTTCAG, 3′-TT
CTGCCAGTGCCTCTTTGCTG; PRDM1 5′-AGAAGGCTC
CAGCCATCTCTGT, 3′-TGCTGGTAGAGTTCGGTGCAGA.
Threshold values (CT) were averaged over each sample replicate,
followed by normalization via the ΔΔCT method to β-actin. For
Western blot analysis, 2 days postnucleofection, naive B cells
were stimulated with mock or anti-IgM+ CpG-B for 24 h and
then harvested for lysate preparation in RIPA buffer (10 nM
Tris–HCl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% Sodium
Deoxycholate, 0.1% SDS, and 140 mM NaCl) (36).

IRF5 ChIP-Seq

Primary naive B cells were isolated as previously outlined and
plated at a density of 1 × 106/mL. B cells were either mock or
anti-IgM+ CpG-B stimulated for 4 h at 37°C in Iscove’s Modified
Dulbecco’s Media (Thermo Fisher) supplemented with 10% FBS.
Cells were subsequently washed 2× in PBS-Ca2+-Mg2+ and fixed
in 1% methanol-free paraformaldehyde for 10 min at 37°C. The
cross-linking reaction was quenched by the addition of glycine
to a final concentration of 0.125 M. Cells were then washed 2× in
PBS-Ca2+-Mg2+ and the final cell pellet lysed in 300 μL of RIPA
lysis buffer. Lysates were loaded into a Covaris sonication microtube and sonicated in a Covaris S2 immersion sonicator with a
duty cycle of 5%, intensity 2, at 200 burst for 15 cycles at 1 min
each. Lysates were then precleared with 75 µL of a 50% agarose
protein a/g bead slurry for 1 h. IRF5 immunoprecipitation (IP)
was performed overnight at 4°C on precleared lyates using 4 µg
of validated IRF5 antibody (Abcam#: ab124792) (34). A 40%
protein a/g bead slurry was added to each IP for 3 h to allow
conjugation of IRF5 antibody to beads. IP bead samples were
then washed 3× in each of the following buffers in order—RIPA
lysis buffer, LiCl wash buffer (100 mM Tris pH 7.5, 500 mM LiCl,
1% NP-40, 1% sodium deoxycholate), and TE buffer (10 mM
Tris–HCl pH 7.5, 10 mM Na2EDTA). IP Beads were incubated
overnight in elution buffer (1% SDS/0.1 M NaHCO3) at 65°C to
reverse cross-links. Eluted DNA was then treated with RNAse
(0.5 mg/mL) and Proteinase K (10 mg/mL) for 2 h each before
isolation using phenol chloroform extraction. Briefly, an equal
volume of phenol chloroform was added to each sample, followed by vigorous vortexing. The mixture was then transferred
to a phase lock tube, spun for 5 min at max speed, and the aqueous phase removed. Repeated ethanol precipitation was used
to isolate final DNA. Resulting ChIP DNA was quantified by
bioanalyzer to ensure sufficient yield and proper fragmentation.
Samples were submitted to the New York University (NYU)
Genome Center for library preparation and single-end sequencing on Illumina HiSeq to a read depth of 50 million reads. Ramos
B cell samples were submitted to the Rutgers NJMS Genomic
Sequencing Core for ChIP-Seq.

In Vitro B Cell Activation and
Plasmablast Differentiation

Isolated naive B cells were cultured in 96-well U-bottom plates
at a minimal density of 1 × 106 with either 150 ng/mL CD40L
(Peprotech #310-02) alone or with 100 ng/mL IL21 (Peprotech
#200-21), 10 µg/mL anti-IgM antibody (Southern Biotech
#2020-01), and 2.5 µg/mL CpG-B (Hycult Tech #HC4039). For
plasmablast differentiation, isolated naive B cells were cultured
for 7 days in the presence of stimulating cocktail.

Flow Cytometry Analysis

Isolated B cells were washed and stained with Live/Dead viability
discrimination dye (Life Tech #L34968). Cells were subsequently
blocked in 2% BSA supplemented with Fc Blocker (BioLegend)
for 15 min and then stained with antibodies against B cell surface makers for 1 h [all antibodies were from BD Biosciences
except CD38-PE/Texas Red (Life Technologies #MHCD3817);
CD19-BV510, #562847; CD20-BUV396, #563782; CD27-BV421,
#560448; IgD-APC, #348222; IgM-PerCP/Cy5.5, #314512;
CD138-PE, #552026; IgG-PE/Cy7, #409316; CD45-APC/Cy7,
#368516]. After staining, cells were washed two times in PBS
without Mg++ or Ca2+ and then fixed in 2% PFA before analysis
on a BD Fortessa or BD LSR flow cytometer. Plasmablasts were
defined as CD19+CD20+IgD−CD27+CD38+ B cells. B cell activation was determined with CD86 surface staining (#562432).
Ig production was determined by intracellular staining with
anti-IgA (Life Tech #Z25002), anti-IgE (Biolegend #325510),
and anti-IgG antibodies in plasmablasts; AID was detected with
antibody #Z25302 (Life Tech). For intracellular IRF5 staining,
after overnight fixation, cells were permeabilized the following
day in 0.1% Triton X-100 and rinsed in PBS 2× before blocking
in 2% BSA solution. IRF5 staining was performed using antiIRF5 antibody conjugated to Alexa Fluor 488 (Abcam Catalog#:
AB193245).

RNA-Seq of Primary Human B Cells

Isolated primary B cells nucleofected with mock, scrambled, or
IRF5 siRNA were mock or anti-IgM+ CpG stimulated for 6 h at
37°C. RNA was purified using the Qiagen RNeasy isolation kit
and on-column DNA digestion performed to remove genomic
DNA. Final RNA was eluted in 30 µL RNAse-free water and
submitted to the NYU Genome Center for single end sequencing
on Illumina HiSeq to a depth of 20 million reads in the case of
primary B cells and 40 million reads for Ramos B cells.

IgG Isotype ELISA

Secretion of IgG isotypes was determined in media from 7-day
cultures by ELISA (ThermoFisher #991000), as per manufacturer
instructions.

Bioinformatics Analysis of ChIP-Seq
and RNA-Seq Data

Proliferation Assay

Nucleofected cells were stained with 2.5 µM CFSE proliferation
dye (Life Tech #C34554) or Cell Trace Violet dye (Life Tech
#C34557) for 20 min. Cells were then washed, plated, and
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ChIP-Seq data was processed by HiChIP (37). Reads were
mapped to the Hg19 human reference sequences using BWA
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at default parameters (38). Peaks were called using the MACS2
algorithm at the following parameters (p = 0.0001, m = 10.30)
and using IgG isotype controls as input against IRF5 ChIP treated
samples. Motif enrichment analysis was performed using the
TomTom Motif Comparison suite (MEME Suite 4.8) (39). Peaks
were visualized using IGV genome browser (40). RNA-Seq data
QC, read mapping by STAR (41), read counting by featureCounts
(42) were handled through the QuickRNASeq pipeline developed
at Pfizer (43). Subsequently, EdgeR was used to determine differentially expressed genes; a p-value ≤ 0.05 and a false discovery
rate (FDR) <0.05 after Benjamin-Hochberg correction was used
for determining significant differential gene expression (44).
Normalized RNA-Seq data are presented as reads per kilobase
of transcript per million reads mapped (RPKM) (45). The QC
report, processed read count table, RPKM table, and interactive
data exploring tool generated by QuickRNAseq is available at
https://baohongz.github.io/IRF5_knockdown. We used HOMER
(46) for pathway analysis as it contains a program for performing functional enrichment analysis from a list of genes (http://
homer.ucsd.edu/homer/microarray/go.html) HOMER uses
a one-sided Fisher’s exact test to determine the significance of
over-representation of a gene set in the input list. We focused our
analysis on enriched pathway gene sets from WikiPathways (47)
as it is the most comprehensive open source pathway collection.
A more stringent cutoff of log2 fold-change ≥1 and FDR ≤ 0.001
was applied to select differentially expressed genes before performing the enrichment analysis to minimize the impact of false
positives due to the small sample size.

BCR stimulation, known to upregulate TLR9, with CpG-B and
examined IRF5 activation (52). Anti-IgM plus CpG-B also
provided a significant increase in IRF5 nuclear translocation
over mock (Figures 1A,B). Since ASC differentiation can utilize
T cell-mediated signals, we examined IRF5 activation following
stimulation with CD40L and IL21. Although we did not detect an
increase in IRF5 activation with CD40L and IL21, the combination of CD40L, anti-IgM, IL21, and CpG-B significantly increased
IRF5 nuclear translocation to levels seen with anti-IgM and
CpG-B (Figures 1A,B).
In murine monocytes, IRF5 nuclear translocation was shown
to increase linearly over time following stimulation (24). We
measured IRF5 activation kinetics in human B cells following
anti-IgM+ CpG-B stimulation. Significant IRF5 nuclear translocation was first observed at 1 h, with peak translocation occurring
at 4 h (Figure 1C). To determine if activation is a byproduct of
increased expression, we measured IRF5 protein levels in total
B cells following 2 h stimulation; no significant difference in IRF5
levels was detected (Figures S1C,D in Supplementary Material).
Although IRF5 expression was unchanged at this early time point
of activation, IRF5 expression across B cell subsets may differ
and has not previously been measured. In monocytes, increased
IRF5 expression is known to be deterministic of subset fate, with
higher IRF5 levels seen in inflammatory M1 macrophages (33). To
determine if IRF5 expression has similar traits in B cells, we quantified expression in B cell subsets from healthy donors. Routine
vaccination is known to increase the occurrence of plasmablasts
and plasma cells in the periphery 7 days post-immunization
(53). We therefore utilized peripheral blood from individuals
immunized with the flu vaccine to define IRF5 protein levels in
CD19+CD20+ naive (IgD+CD38−CD27−CD24−), transitional
(IgD+CD38+CD27−CD24+), non-switched memory (IgD+CD3
8−CD27+CD24−), switched memory (IgD−CD27+CD24−), plasmablasts (IgD−CD38hiCD27+CD24−CD138−), and plasma cells
(IgD−CD38hiCD27+CD24−CD138+) (Figure 1D). Naive and transitional B cells expressed lower levels of IRF5 protein, whereas both
non-switched and switched memory had increased expression.
Plasmablasts and plasma cells had the highest IRF5 expression
(Figures 1E,F). Similar findings were made in blood from healthy,
non-vaccinated individuals (Figures S1E,F in Supplementary
Material). These data suggest that IRF5 may regulate both B cell
subset fate and effector function in mature B cell populations.

Statistical Analyses

Unless otherwise stated, one-way ANOVA or two-way ANOVA
were used to compare means among three or more independent
groups. Bonferroni posttest to compare all pairs of data sets was
determined when overall p-value was <0.05. All statistical analyses were performed using GraphPad Prism (version 7.0). Data
are reported as mean ± SD. In each figure legend, the number
(n) of biological repeats included in the final statistical analysis is
indicated. p-value < 0.05 was considered significant.

RESULTS
TLR9/BCR Stimulation Induces
IRF5 Nuclear Translocation

IRF5 Knockdown Reduces ASC
Differentiation

Among the pathways known to play a role in ASC differentiation
is TLR signaling (48). IRF5 acts downstream of TLRs in monocytes and dendritic cells, but characterization of IRF5 activation in human B cells has not been shown. IRF5 resides in the
cytoplasm of unstimulated cells and upon activation translocates
to the nucleus (49–51). We examined IRF5 activation following
treatment of healthy CD19+ B cells with activating stimuli using
imaging flow cytometry (gating in Figure S1B in Supplementary
Material). We failed to detect significant IRF5 nuclear translocation with BCR activating anti-IgM antibody or T cell-dependent
CD40L but detected significant activation with the TLR9 agonist
CpG-B (Figures 1A,B). As the majority of peripheral B cells
are antigen naive and express low levels of TLR9, we combined
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To investigate the role of IRF5 in human ASC differentiation, we
validated and optimized targeted IRF5 knockdown in human
primary naive B cells using nucleofection (36, 54, 55). Isolated
naive B cells were nucleofected with mock, ON-TARGETplus
non-targeting control pool (scrambled), or SMARTpool
ON-TARGETplus human IRF5 siRNA. IRF5 knockdown efficiency was quantified by measuring IRF5 transcript and protein
levels. A 50% reduction in IRF5 transcript levels was detected
24 h postnucleofection in comparison to mock and scrambled
(Figure 2A). To ensure that a reduction in transcripts correlated
with a reduction in IRF5 protein levels, protein lysates were
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Figure 1 | Toll-like receptor 9/B cell receptor stimulation induces Interferon regulatory factor 5 (IRF5) nuclear translocation. (A) Representative images of IRF5
cellular localization in human CD19+ B cells from a single healthy donor that were stimulated with mock, anti-immunoglobulin (Ig) M antibody, CD40 ligand (CD40L),
CpG-B, or CD40L and IL21, and the combination of anti-IgM antibody, CD40L, IL21, and CpG-B for 2 h. PBMC were surface-stained with anti-CD19 antibodies,
fixed and permeabilized, then stained for intracellular IRF5 and nuclear DRAQ5. Samples were then subjected to imaging flow cytometry followed by analysis in the
IDEAS software suite. (B) Frequency of cells in (A) with IRF5 nuclear translocation, which was defined by an IRF5 and DRAQ5 similarity score ≥2 (one-way ANOVA
with Tukey’s post hoc test; n = 4 independent donors). (C) IRF5 nuclear translocation was quantified over 12 h in isolated B cells following stimulation with anti-IgM+
CpG-B. Data was normalized to mock to minimize donor variability (one-way ANOVA with Tukey’s post hoc test; n = 4 independent donors). (D) Representative
gating strategy for human B cells subsets in peripheral blood of healthy donors who received the influenza vaccine 7 days prior to phlebotomy. B cell populations
were defined as CD19+CD20+ naive (IgD+CD38−CD27−CD24−), transitional (IgD+CD27−CD38+CD24+), non-switched memory (NSM; IgD+CD27+CD38−CD24−),
switched memory (SM; IgD−CD27+CD24−), plasma blasts (PB; IgD−CD38hiCD27+CD24−CD138−), and plasma cells (PC; IgD−CD38hiCD27+CD24−CD138+). (E)
Representative histograms of IRF5 protein expression in B cell subsets gated in (D). (F) Average MFI of IRF5 expression in gated B cell subsets (two-way ANOVA
with Tukey’s multiple comparison post hoc test; n = 5 independent donors). Error bars represent SD. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

prepared at 72 h postnucleofection (with 24 h anti-IgM plus
CpG-B stimulation) and analyzed by Western blot and flow
cytometry (Figures 2B–D). Costimulation provided an increase
in IRF5 expression levels over mock unstimulated, and these levels were significantly reduced following nucleofection with IRF5
siRNA, while IRF5 levels remained steady in mock and scrambled
controls supporting the specificity of knockdown. Notably, analysis by flow cytometry showed reduced IRF5 expression amongst
the total population of viable B cells in comparison to scrambled

Frontiers in Immunology | www.frontiersin.org

control. Stimulation with anti-IgM and CpG-B did not impact
IRF5 knockdown efficacy (Figures 2A,B).
Interferon regulatory factor 5 is known to regulate the transcription of pro-apoptotic genes following DNA damage or death
receptor signaling (56, 57). To quantify B cell viability following
IRF5 knockdown, nucleofected naive B cells were stained with
tryphan blue 24 h after mock or anti-IgM and CpG-B stimulation.
Although nucleofection itself results in ~15% reduction in cell
viability, no further decrease in viability was found after IRF5
5
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Figure 2 | Interferon regulatory factor 5 (IRF5) is required for toll-like receptor 9/B cell receptor -induced antibody secreting cell differentiation. Isolated human
naive B cells were nucleofected with 500 nM of mock, scrambled or IRF5 siRNA and mock-stimulated or stimulated with the indicated cocktails. (A) IRF5 transcript
expression was quantified through qPCR on RNA isolated 48 h postnucleofection and 12 h poststimulation with anti-IgM+ CpG-B (two-way ANOVA with Tukey’s
post hoc test; n = 4 independent donors). (B) Protein lysates were prepared from nucleofected B cells 72 h postnucleofection and 24 h poststimulation with
anti-IgM+ CpG-B. Western blot is one representative experiment out of three performed on n = 3 independent donors. (C) Representative histograms of IRF5
expression 48 h postnucleofection. Viable cells were analyzed through live/dead staining discrimination. (D) Plotted MFI of IRF5 from (C) (one-way ANOVA with
Tukey’s post hoc test; n = 4 independent donors). (E) Plotted percentage of B cell viability assessed 72 h post-nucleofection, as determined through trypan blue
exclusion. Data are from n = 3 independent donors. (F) Representative dot plots from B cell apoptosis quantified following staining with Annexin V and 7 aminoactinomycin D (7-AAD). Early apoptotic events are characterized as Annexin V+ 7AAD−, whereas late apoptotic events are Annexin V+ 7AAD+. Quantitation is shown
in (G). (G) Average apoptotic B cells from (F) 96 h post-nucleofection and 48 h post-stimulation (Two-way ANOVA with Tukey’s post hoc test; n = 3 independent
donors). (H) Isolated naive B cells were nucleofected with 500 nM of mock, scrambled or IRF5 siRNA and stimulated with either CD40L or the combination of
CD40L, IL21, anti-IgM, and CpG-B for 7 days. Plasmablast differentiation was quantified through gating of CD19+CD20+IgD−CD27+CD38+ B cells; final
CD27+CD38+ gating is shown. Flow cytometry contour plots are representative of one experiment from a single donor. (I) Average number of plasmablasts from
(H) following culture for 7 days (two-way ANOVA with Tukey’s post hoc test; n = 9 independent donors). (J) Average number of IgD+CD38lo B cells from
(H) following stimulation (two-way ANOVA with Tukey’s post hoc test; n = 9 independent donors). Error bars represent SD. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

knockdown (Figure 2E). As viability assays often fail to detect
early stages of apoptosis, we assayed B cell apoptosis following
IRF5 knockdown through Annexin V and 7-amino-actinomycin
D (7-AAD) staining. CD40L treatment did not induce significant
levels of apoptosis, whereas stimulation with CD40L, IL21, antiIgM, and CpG-B induced a similar increase in apoptosis across
all three siRNA conditions (Figures 2F,G). Upon exposure to
antigen, only a small proportion of naive B cells will be selected to
undergo ASC differentiation, thus the observed increase in apoptosis by the combination treatment is not surprising. However,
Frontiers in Immunology | www.frontiersin.org

IRF5 knockdown did not result in a significant decrease in
apoptosis in comparison to control conditions (Figure 2G). This
indicates that under the current experimental conditions, IRF5
does not have a significant impact on B cell viability or apoptosis.
Following stimulation, B cells rapidly proliferate and differentiate to ASCs. In an effort to measure ASC generation from
the population of naive B cells showing IRF5 knockdown, naive
B cells were conucleofected with GFP mRNA and IRF5 siRNA.
Unfortunately, only ~20% of naive B cells expressed GFP and
no correlation between GFP and IRF5 knockdown was found
6
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(Figures S2A–C in Supplementary Material). Similar effects were
seen with pmaxGFP™; in this case, only ~2–4% of naive B cells
expressed GFP (Figures S2D,E in Supplementary Material). Thus,
cells were nucleofected as before and cultured for 2 days, followed
by stimulation with CD40L or anti-IgM, CpG-B, CD40L, and
IL21 for 7 days. These stimulation conditions result in a significant increase in IgD−CD27+CD38+ plasmablasts (6, 58), as seen
in both mock and scrambled control (Figures 2H,I, flow gating
in Figure S3A in Supplementary Material). In contrast to these
controls, IRF5 knockdown resulted in a two-fold reduction in
plasmablast differentiation. Additionally, the percentage of IgD+
B cells present following stimulation was significantly increased
after IRF5 knockdown (Figure 2J; Figure S3B in Supplementary
Material). Similar to that observed in the circulation of influenzavaccinated healthy donors (Figures 1E,F), increased IRF5
expression was detected in B cells over the 7-day in vitro culture
period. As expected, naive B cells expressed the lowest levels of
IRF5 and plasmablasts expressed the highest (Figures S2F,G in
Supplementary Material). Together, these data indicate that IRF5
has a B cell-intrinsic role in human ASC differentiation.

consequential reduction in secreted antibody. We first measured
percentages of nucleofected B cells expressing intracellular IgA,
IgE, or IgG following stimulation for 5 days using flow cytometry. Intracellular Ig staining is indicative of the fraction of B cells
that may secrete a specific antibody isotype. Representative
flow gating for IgG in total CD19+CD20+ B cells is shown in
Figure 3D. While few B cells expressed intracellular IgA or
IgE, a large fraction of B cells stained positive for IgG. IRF5
knockdown resulted in a significant reduction in intracellular
IgG staining (Figure 3E). IRF5 has previously been linked to
IgG isotype secretion in mice, with Irf5−/− mice having reduced
IgG2a levels following viral infection and in murine models
of lupus (21, 22). As IL21 and CpG have both been shown to
predominantly promote IgG secretion (59), we further measured
IgG isotypes by ELISA. Following stimulation, IRF5 knockdown
resulted in significantly decreased levels of IgG1, 2, and 3 but
not 4 (Figure 3F). Since IgG2 and 4 were only secreted to a low
extent, the largest impact was among the IgG1 and 3 isotypes.
To determine if the reduction in IgG expression was due to a
reduction in CSR, we assayed AID expression. AID expression
is transcriptionally regulated, with expression quickly upregulated following B cell activation and proliferation. Interestingly,
expression of AID was significantly decreased following IRF5
knockdown (Figure 3G). These data indicate that IRF5 contributes to early stages of ASC differentiation.

IRF5 Knockdown Impairs B Cell
Proliferation and Activation

Stimulation of B cells results in a rapid proliferative burst, which
is required for sufficient numbers of antigen-specific B cells
to survive CSR. To investigate if a decrease in the number of
B cells entering proliferation is responsible for the reduction in plasmablasts seen after IRF5 knockdown, we assayed
B cell proliferation. Nucleofected B cells were labeled with
the proliferation dye CFSE, stimulated with anti-IgM, CpG-B,
CD40L, and IL21 for 5 days, and CFSE dilution determined
through flow cytometery by gating on viable cells (Figure S3A
in Supplementary Material). A significant reduction in the
number of naive B cells undergoing proliferation was seen following IRF5 knockdown (Figures 3A,B). Compared to mock
and scrambled controls, IRF5 knockdown resulted in a twofold
reduction in proliferation.
B cell activation occurs immediately following antigen recognition, and can occur through each of the previously described
activation pathways. CpG-B stimulation of naive B cells can
upregulate expression of the activation marker CD86 (6). As B cell
activation primes for proliferation, we assayed activation following IRF5 knockdown. Primary naive B cells were nucleofected
and stimulated for 2 days. Stimulation induced the upregulation
of CD86 expression in both mock- and scramble-nucleofected
B cells, whereas IRF5 knockdown significantly reduced CD86
expression (Figure 3C). IRF5 is known to function downstream
of TLR9, which has previously been shown to be involved in the
upregulation of CD86 (52, 58). These data indicate that IRF5 acts
downstream of TLR9/BCR to induce early B cell activation and
proliferation.

Identification of New IRF5 Target Genes
Associated with ASC Differentiation

Interferon regulatory factor 5 initiates transcription of target
genes following nuclear translocation; however, IRF5 target
genes in B cells have not been characterized. We performed
chromatin IP combined with deep sequencing (ChIP-Seq) to
identify IRF5 transcriptional targets across the genome in human
primary naive B cells. To ensure IRF5 is specifically enriched in
ChIP experiments, previously validated antibodies were used
for IP (36). ChIP-Seq libraries were prepared from both mock
and anti-IgM+ CpG-B-stimulated cells (4 h) to characterize
activation-dependent targets of IRF5. Computational analysis
revealed a sharp increase in the number of IRF5 peaks following
stimulation. In mock-treated samples, IRF5 bound 22 genes, and
upon treatment with anti-IgM+ CpG-B, IRF5 targets increased to
784. IRF5 genome occupancy was distributed across various gene
elements with 3.5% of peaks occurring within ±3 kb of putative
transcription start sites (Figure 4A). Additionally, a large majority of peaks were found on intragenic regions. Roughly 10.5% of
peaks were bound to exons, and 21% were bound to non-coding
regions.
Interferon regulatory factor family members bind to
IFN-stimulated response elements (ISREs) consisting of the
GAANNGAA motif. IRF5, however, can partner with other
transcription factors to recognize various consensus sequences.
It was recently reported that IRF5, in cooperation with RelA of
the NFĸB pathway, can recognize composite PU.1/ISRE motifs
in murine inflammatory monocytes (60). IRF5 consensus sites
have not been well-defined in humans. We therefore sought to
determine if IRF5 recognizes similar motifs in human B cells.

IRF5 Knockdown Reduces Human
IgG1 and 3 Secretion

Given the reduction in plasmablast differentiation seen after
IRF5 knockdown, we determined whether there would be a
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Figure 3 | Continued
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Figure 3 | Interferon regulatory factor 5 (IRF5) knockdown impairs B cell proliferation, activation, and immunoglobulin (Ig) G isotype secretion. (A) Representative
flow cytometry histograms from cell proliferation assay as measured through dilution of the proliferation dye CFSE. Isolated primary naive B cells from a single donor
were nucleofected with 500 nM of mock, scrambled or IRF5 siRNA and stimulated with either CD40 ligand (CD40L) or the combination of CD40L, IL21, anti-IgM,
and CpG-B for 5 days. (B) Average percentage of proliferating B cells from (A) is shown (two-way ANOVA with Tukey’s post hoc test; n = 5 independent donors).
(C) Average percentage of B cells expressing CD86. Similar to (A) except isolated naive B cells were nucleofected and then stimulated with CD40L, IL21, anti-IgM,
and CpG-B for 24 h, then stained for surface CD86 (two-way ANOVA with Tukey’s post hoc test; n = 5 independent donors). (D) Representative contour plots from
IgD−IgG+ B cells after gating on total CD19+CD20+ B cells. Isolated primary naive B cells were nucleofected with 500 nM of mock, scrambled or IRF5 siRNA and
stimulated with either CD40L or the combination of CD40L, IL21, anti-IgM, and CpG-B for 7 days. (E) Quantification from (D) of Ig antibody class expression was
determined by intracellular flow cytometery (one-way ANOVA with Tukey’s post hoc test; n = 5 independent donors). (F) Cell culture supernatants from (D) were
used for ELISA to determine IgG isotype secretion. Average concentration of IgG isotype is shown (two-way ANOVA with Tukey’s post hoc test; n = 4 independent
donors). (G) Frequency of activation-induced deaminase (AID) expression in B cells following nucleofection with 500 nM of mock, scrambled or IRF5 siRNA and
stimulated with CD40L, IL21, anti-IgM, and CpG-B for 3 days. AID expression was determined by intracellular flow cytometry (one-way ANOVA with Tukey’s
post hoc test; n = 5 independent donors). Error bars represent SD. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

Figure 4 | Interferon regulatory factor 5 (IRF5) binds promoter regions of genes associated with antibody secreting cell (ASC) differentiation. IRF5 ChIP-Seq was
performed on isolated primary naive B cells from n = 2 independent donors. B cells were either mock or anti-IgM+ CpG-B stimulated for 4 h. Reads were mapped
through BWA and peaks called through MACs. (A) A pie chart showing representative IRF5 binding elements throughout the human primary B cell genome.
(B) Common IRF5 binding motifs identified from ChIP-Seq. Motif sequences are shown in order of enrichment with associated transcription factor motif.
(C) Representative peak distributions are shown for IRF4, ERK1, CASP5, and MYC. Peaks are boxed in red and were determined at a significance of p ≤ 0.0001.
(D) Same as (C) except IRF5 ChIP-Seq peaks are from the Ramos B cell line. Peaks were determined at p ≤ 10−10. (E) Independent confirmation of IRF5 binding
to IRF4, MYC, and ERK1 target sites through ChIP-qPCR in primary naive B cells mock stimulated or stimulated with anti-IgM+ CpG-B for 4 h (two-way ANOVA
with Tukey’s post hoc test; n = 4 independent donors). Error bars represent SD. *p ≤ 0.05; ***p ≤ 0.001.
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Figure 5 | Identification of an interferon regulatory factor 5 (IRF5)-dependent B cell transcriptome. Isolated naive B cells were nucleofected with 500 nM of mock,
scrambled or IRF5 siRNA and subsequently stimulated with anti-IgM and CpG for 6 h. RNA-seq was performed on B cells from n = 2 independent donors.
(A) Significant donor correlation associated with IRF5 knockdown and stimulation. Heat map illustrates correlation coefficients for gene expression values between
conditions (nucleofection and stimulation) and individual healthy donors. A strong correlation between samples is indicated by the red and pink boxes. Color legend
is shown to the right indicating correlation coefficients. (B) Identification of genes with differential expression following IRF5 knockdown in mock-treated samples.
Red circles indicate downregulated genes; green circles indicate upregulated genes. Differential gene expression was determined in comparison to scrambled
control. (C) Same as (B) except genes were identified following IRF5 knockdown and stimulation (CpG-B+ anti-IgM). Differential expression was determined by
comparison to stimulated scrambled control. (D) Diagram of differential expression between nucleofection and various stimulation conditions. Overlapping regions
represent shared expression; single regions represent uniquely expressed genes. (E) Heat map of gene expression between the two donors based on cellular
function associated with B cell activation, proliferation, and antibody secreting cell differentiation. Data are expressed as log2RPKM. (F) Raw RPKM values of
particular genes relevant to IRF5 function. p values and false discovery rate (FDR) scores were obtained by multiple comparisons testing of samples indicated by
line. Individual p values and FDR scores are included in each graph. (G) Independent confirmation of differential gene expression through qPCR (two-way ANOVA
with Tukey’s post hoc test; n = 3 independent donors). Error bars represent SD. **p ≤ 0.01.

Using motif discovery algorithms, we identified common motifs
within 100 bp of peak centers. Among the represented motifs was
the expected ISRE consensus sequence, as well as a newly identified IRF5/RUNX motif that was equally enriched for (Figure 4B).
These data suggest cooperation between IRF5 and RUNX family
members in the targeting of genes following B cell activation.
Interferon regulatory factor 5 was found to bind a wide range
of genes, including several associated directly with ASC differentiation. Among these targets were IRF4, ERK1, and CASP5
(Figure 4C). While these genes are implicated in ASC differentiation and were targeted by IRF5 in human primary B cells
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following activation, none seemed to fully account for the early
defects in B cell proliferation or activation (Figures 3A–C). As
a result, there remained the possibility that several target genes
were missing due to limitations, possibly, in obtaining sufficient
numbers of primary naive B cells at the 4 h time point of IRF5
activation (Figure 1C). To ensure the identification of all possible IRF5 target genes, we performed IRF5 ChIP-Seq in Ramos
B cells. Ramos are known to express high levels of TLR9, and
thus recapitulate early stages of primary naive B cell activation
following anti-IgM+ CpG-B stimulation (61). Enriched reads
from Ramos B cells were similarly distributed as in primary
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Table 1 | List of top differentially expressed genes comparing mock-treated
with scrambled siRNA against IRF5 knockdown.a

Table 2 | List of top differentially expressed genes comparing anti-IgM+ CpG-B
stimulated with scrambled siRNA against IRF5 knockdown.a

Upregulated genes in mock-treated cells

Upregulated genes in anti-IgM+ CpG-B-treated cells

Geneb

Function

NR4A1

FCRL4

Member of the Ig receptor superfamily; acts as an inhibitor
of B cell activation

ADAMTS7

Plays a role in activation of vascular smooth muscle cells.
Unknown role in B cells

Hormone nuclear receptor and transcription factor. Involved in cell
cycle progression and regulation of apoptosis. NR4A1(Nur77)deficient mice display increased B cell survival among CD38+
B cells. Increased autoantibody production also observed

LMNA

See above

ID3

Transcriptional regulator of basic helix-loop-helix family of
transcription factors. Implicated in cell growth, apoptosis, and
differentiation. Required for germinal center formation but acts as a
negative regulator of plasma cell differentiation

LPXN

Leupaxin, a negative regulator of paxilin signaling. Negative regulator
of BCR signaling

LMNA

Lamin A/C, major component of the nuclear lamina. Important
in maintaining integrity of nuclear structure; involved in
chromosome segregation during mitosis

PPP1R15A

Recruits protein phosphatase 1, which suppresses stress
kinase-induced protein expression. Expression upregulated
during cellular stress or DNA damage

AMICA1

Adhesion molecule expressed on cell surface; primarily
on T cells. Function in B cells remains unclear

NR4A2

Hormone nuclear receptor and transcription factor

CAPN2

CD109

A glycosyl phosphatidylinositol (GPI)-linked glycoprotein that
localizes to the cell surface. Acts as a TGF-b coreceptor which
stimulates internalization and degradation of TFG-b receptors

Calpain 2, an intracellular cysteine protease. Regulates cell
migration; is a Pax5 target gene in B cells

ARL4C

Small GTP binding protein and member of ADP-ribosylation factor
family. Regulates microtubule dependent intracellular vesicular
transport

FLNA

Filamin A, an actin binding protein responsible for cross-linking of
actin filaments. Plays a role in regulating cell shape and structure

UPP1

Catalyzes cleavage of uridine and deoxy-uridine to uracil and
ribose- or deoxyribose-1-phosphate

SLC3A2

Cell surface transmembrane protein which makes up the heavy
chain of the amino acid transporter CD98. Acts as an integrin
binding protein. Shown to be required for B cell proliferation and
antibody responses

SQSTM1

ADAMTS7 See above

Downregulated genes in anti-IgM+ CpG-B-treated cells

Sequestosome 1, a multifunctional signaling protein known to
be an autophagy target as well as an ubiquitin binding scaffolding
protein involved in NFkB activation through interaction with TRAF6

Downregulated genes in mock-treated cells
LTB

Lymphotoxin beta, membrane protein of the TNF family.
Inflammatory B cell cytokine

CHI3L1

Member of chitanase family of proteins; lacks chitanse activity.
Unclear role in B cells

MKI67

Ki67, surfactant required for chromosome segregation in
proliferating cells. Used as marker of proliferating cells

TCL6

Non-coding RNA of unknown function

CPNE5

Copine 5, calcium binding protein involved in regulating
cell signaling

TRIB2
CD72

Member of tribble family of serine/threonine kinases.
Regulates TLR5-mediated NFkB activation
Membrane protein containing ITIM motifs and C-type lectin
domains. Negative regulator of BCR-mediated signaling by
suppression of calcium mobilization. Recently shown to regulate
B cell autoreactivity following TLR7 ligation with autoantigen Sm/
RNP

CORO2B

Coronin 2B protein coding gene of unknown function

FAM129C

B cell novel protein 1, unknown signaling protein

Ig-like receptor expressed on cell surface. Receptor for bone
marrow stromal cell antigen-2; may be involved in regulating early
B cell development

BATF3

Basic Leucine Zipper transcription factor within the AP-1 family of
transcription factors. Interacts with Jun as a transcriptional regulator
in several immune cell populations

CHI3L1

See above

HAPLN3

Member of hyaluronan and proteoglycan binding link protein gene
family; major component of extracelluar matrix. Recently shown to
be upregulated in IFNb-stimulated B cells

MYBL2

Member of MYB transcription factor family; regulates cyclin D1
expression. Regulates cell cycle progression. Highly expressed
during early B cell development

GCA

Grancalcin, a calcium binding protein that interacts with TLR9 to
mediate IRF7- and NFkB-dependent type 1 interferon expression

SLC2A5

Acts as a fructose transporter. Unclear role in B cells

CR2

Complement receptor 2; binds complement factor C3Dd. Involved
in B cell activation

LTA

Lymphotoxin alpha; member of TNF family of cytokines. Mediates
inflammatory and cytotoxic effects on various target cells

a
Comparing gene expression between scrambled siRNA and IRF5 siRNA nucleofected
samples.
b
p–Value ≤0.05 and an FDR < 0.05 after Benjamin–Hochberg correction was used for
determining significant differential gene expression. Genes are from Figure 5.

Comparing gene expression between scrambled siRNA and IRF5 siRNA nucleofected
samples.
b
p–Value ≤0.05 and an FDR < 0.05 after Benjamin–Hochberg correction was used for
determining significant differential gene expression. Genes are from Figure 5.
a

these was the proliferation gene MYC, and NFKB1 (Figure 4D).
To confirm that results from Ramos B cells were applicable to
primary B cells, IRF5 ChIP-qPCR was performed on pooled
primary naive B cells. Significant enrichment was seen on IRF4,
MYC, and ERK1 following IRF5 ChIP (Figure 4E). Interestingly,
MYC is downstream of ERK1 and an ERK1-Elk-Myc signaling
pathway has been implicated in early B cell proliferation (8, 62).

B cells (Figure S4A in Supplementary Material). Importantly,
identical target genes, such as IRF4 and CASP5, were identified
in both datasets (Figures 4C,D). Several additional target genes
not seen in primary B cells were identified in Ramos. Among
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or anti-IgM+ CpG-B stimulated for 6 h; the 6 h timepoint was
chosen to account for early IRF5-mediated gene transcription
occurring in response to nuclear IRF5 at 4 h poststimulation
(Figure 1C). RNA-Seq was performed on two independent
biological replicates showing a strong correlation coefficient
between gene expression (Figure 5A). Bioinformatics analysis
found a dramatic shift in the transcriptome of B cells following
knockdown (Figures S4B,C in Supplementary Material). After
knockdown in mock-treated cells, 1,217 genes were downgregulated while 865 genes were upregulated (Figure 5B). The
most differentially expressed genes following IRF5 knockdown
in the mock-treated group are listed in Table 1 (and shown in
Figure S4B in Supplementary Material). Genes such as FcRL4
and SLC3A2, which were significantly upregulated following
IRF5 knockdown, have been shown to regulate B cell activation and proliferation. FcRL4 is known to act as an inhibitor
of BCR signaling (63). SLC3A2 was shown to be important for
B cell proliferation and plasmablast differentiation in mice (64).
Alternatively, the B cell cytokine LTB, as well as the proliferation
marker Ki67 were found to be significantly downregulated after
IRF5 knockdown (65). Following stimulation, IRF5 knockdown
resulted in 2,755 downregulated and 2,995 upregulated genes
(Figure 5C). Among the most differentially expressed genes
within this group (Figure S4C in Supplementary Material;
Table 2), which are relevant to B cell activation, included the
upregulated genes ID3 and NR4A1 (66–68). Both have been
shown to be involved in B cell activation and proliferation. In
contrast, the B cell-associated cytokine LTA and the proliferation
marker Ki67 were found both to be significantly downregulated.
Differential expression contrasts between stimulated
mock-, scrambled-, and IRF5-nucleofected samples identified
several genes uniquely modulated following IRF5 knockdown
(Figure 5D). While several of these genes showed significant
differential expression and have been previously implicated in
B cell biology, they failed to intuitively explain the observed
reduction in B cell proliferation and differentiation. As a result,
we performed a further gene expression analyses focused on
genes relevant to B cell activation, proliferation, and ASC
differentiation (Figure 5E). Confirmation of our stimulation
conditions was seen through the significant upregulation of
genes involved in ASC differentiation (IRF4, XBP1, PRDM1),
inflammatory cytokine expression (LTA, LTB), and proliferation
(MYC, CDK4) (Figure 5E). Analysis of differential expression
following IRF5 knockdown revealed a significant decrease in
many of the genes (Figures 5E,F). As expected, expression of
inflammatory cytokines such as IL6, LTA, LTB, and IL12A was
significantly reduced following knockdown. Among the genes
known to regulate ASC differentiation, expression of PRDM1,
AICDA, and MYC were significantly downregulated whereas
expression of IRF4 and XBP1 were not significantly impacted
by IRF5 knockdown at this time point (Figure 5F). This may
suggest that while IRF5 binds to the IRF4 promoter, it is dispensable in IRF4 transcriptional regulation. In contrast, IRF5
occupancy was found on the promoter region of MYC, and a
corresponding significant decrease in MYC gene expression was
seen after knockdown (Figure 5F). Reduction in MYC, and other
genes identified by RNA-Seq, was confirmed by real-time qPCR

Table 3 | List of ASC-associated genes from RNA-Seq that contain potential
ISRE and/or IRF-E sites in their regulatory regions.a
Gene

Chromosome position (Hg19)

ISRE

IRF-E

PRDM1

chr6:106,534,195-106,557,814

106566840,
106547222

106562388

XBP1

chr22:29,190,548-29,196,560

ND

ND

IRF4

chr6:391,739-411,443

391724

409414

IRF5

chr7:128,577,994-128,590,088

128580725

128594612

PAX5

chr9:36,838,531-37,034,476

ND

36867441,
36868076,
37197361

AICDA

chr12:8,754,762-8,765,442

ND

ND

CD38

chr4:15,779,931-15,850,706

ND

ND

BTK

chrX:100,604,435-100,641,212

ND

100668558

LYN

chr8:56,792,386-56,925,006

56842848,
56863323

6773360,
56793604

BLK

chr8:11,351,521-11,422,108

ND

11349703

IKZF1

chr7:50,344,378-50,472,798

50340355,
50484586

50424402,
50444411,
50484587

IKZF2

chr2:213,864,411-214,015,058

213831888,
214030738,
214014429,
214017464,
214030738

213936673,
214015411,
214017463

STAT3

chr17:40,465,343-40,540,513

40460528

ND

STAT4

chr2:191,894,302-192,016,322

ND

191885173,
191964289

MYC

chr8:128,748,315-128,753,680

ND

ND

MKI67

chr10:129,894,925-129,924,468

ND

ND

IL6

chr7:22,766,766-22,771,621

ND

22763062,
22765259

IL12A

chr3:159,706,623-159,713,806

ND

ND

NFKB1

chr4:103,422,486-103,538,459

103424172,
103560981

103448890,
103459016,
103533964

RELA

chr11:65,421,067-65,430,443

ND

65431520

RELB

chr19:45,504,707-45,541,456

ND

ND

CASP5

chr11:104,864,967-104,893,895

ND

ND

Consensus sequences were identified through UCSC using Hg19 and transcription
factor binding sites that are within 4 kb upstream of the transcription start site (TSS)
and 4 kb downstream of the stop codon.
ND, not detected.
a

These data support that IRF5 directly binds to promoters of genes
important for early stages of B cell activation and proliferation.

Identification of an IRF5-Dependent
B Cell Transcriptome

Identification of IRF5 target genes suggested that IRF5 could
influence the transcription of several genes important for
ASC differentiation. We thus examined changes on the B cell
transcriptome following IRF5 knockdown by high throughput
cDNA sequencing (RNA-Seq). Nucleofected B cells were mock
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in independent donors (Figure 5G). We next examined genes
identified in Figure 5E for IRF-E or ISRE consensus binding
sites in their 5′- and/or 3′-UTR. Results in Table 3 reveal that
while many of the genes do contain consensus binding sites
that IRF5 may recognize, not all do. Instead, IRF5 may utilize
non-classical sequences, such as those identified in Figure 4B for
direct regulation. Altogether, data indicate that one mechanism
by which IRF5 regulates human ASC differentiation is through
the early control of B cell proliferation via direct regulation of
MYC expression followed by alterations in the expression of
other ASC-associated genes.
To gain a further understanding of IRF5-regulated pathways in
primary naive B cells, we performed an in-depth integrative analysis of ChIP-Seq and RNA-Seq datasets. Results in Figures 6A,B
are from pathway analysis showing the top 20 most activated
pathways when compared to mock untreated samples. Data in
Figure 6A show a distinct upregulation in the unfolded protein
response, adipogenesis, and translation factor pathways after
IRF5 knockdown. Conversely, knockdown of IRF5 in untreated
and treated samples resulted in the downregulation of cell cycle
and BCR signaling pathways (Figure 6B). Downregulation of

these pathways coincide with functional defects detected after
IRF5 knockdown (Figures 2 and 3). Given that the NF-κB
signaling pathway has been shown to play a role in murine
ASC differentiation (69), we mapped out genes in this pathway
that were affected by IRF5 knockdown (Figure 6C). We also
mapped out cell cycle and DNA damage signaling genes affected
by IRF5 knockdown since we detected an alteration in BCR/
TLR9-induced cell proliferation (Figure 7). Last, given that early
defects in B cell activation were detected after IRF5 knockdown,
we mapped out the complex interaction of genes involved in the
BCR signaling pathway that were differentially affected (Figure S5
in Supplementary Material). Together, these data implicate IRF5
in the regulation of multiple signaling pathways involved in ASC
differentiation and B cell survival.

DISCUSSION
The differentiation of ASCs is reliant upon a large network of
transcription factors, which are responsive to various B cell activation pathways. Among the B cell activation pathways known
to play a role in ASC differentiation is the TLR signaling pathway

Figure 6 | Continued
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Figure 6 | Interferon regulatory factor 5 (IRF5) regulates numerous biologic signaling pathways in human primary B cells. (A) Data from ChIP-Seq and RNA-Seq
were used to identify the top 20 upregulated pathways in which there were more upregulated genes than downregulated genes as compared to Mock untreated
(NT). Heat map is shown from HOMER analysis with a cutoff of log2FC ≥ 1 representing genes with at least a twofold change in expression and an false discovery
rate (FDR) ≤ 0.001. Pathways are ordered by negative log10 p-values of enrichment. (B) Same as (A) except top 20 downregulated pathways are shown. (C)
Representative scheme showing enrichment of the upregulated NF-ĸB survival signaling pathway after IRF5 knockdown. Boxes representing genes are color-coded
based on the log2 fold-change values. Upregulated (red) or downregulated (blue) genes are shown as compared to Mock NT. Expression is shown by color code in
four sections of each gene box. The gene box is divided into sections with one to one mapping comparisons of IRF5KD_NT, IRF5KD_anti-IgM+ CpG, Scr_anti-IgM+
CpG, and Mock_anti-IgM+ CpG vs. reference Mock_NT, as shown in the Legend.

occurs through nuclear translocation (Figures 1A–C). Whether
this effect is dependent on TLR9/BCR-induced B cell activation
or would occur downstream of other B cell activating pathways is not currently known. However, since previous data in
Irf5−/− mice showed a direct transcriptional role for IRF5 in the
regulation of PRDM1 and the γ2a locus (22, 25), it is intriguing
to consider IRF5 as a global mediator of antibody responses. Our
finding of significantly reduced plasmablast differentiation and
IgG antibody production following IRF5 knockdown highlights
the role of IRF5 in mediating antibody responses. Contrary

(6, 48). IRF5 is known to act downstream of TLR signaling in
monocytes and dendritic cells, but characterization of IRF5 activation in human B cells has not been previously shown. Here we
demonstrate that the transcription factor IRF5 acts downstream
of TLR signaling to drive proliferation and differentiation to
ASCs. However, unlike other transcription factors involved in
ASC differentiation, such as IRF4, PRDM1, XBP1, and MYC that
require early transcriptional upregulation (Figures 5E,F), IRF5
is uniquely poised for the rapid modulation of ASC-associated
gene transcription in human B cells since its early regulation
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Figure 7 | Interferon regulatory factor 5 regulates B cell proliferation and cell cycle. Similar to Figure 6C showing the overall downregulation of the cell cycle and
DNA damage signaling pathway from ChIP-Seq and RNA-Seq datasets. Genes are shown as being either upregulated (red) or downregulated (blue) when
compared to Mock untreated (NT). Representative expression is shown in four sections of each gene box as depicted in the Legend.

to murine data, however, we were unable to detect IRF5 peak
enrichment at PRDM1 or any IgG locus by ChIP-Seq. This may
be due to the early time point of analysis (4 h post-stimulation)
or that these genes do not contain regulatory sequences recognized by IRF5. Similar to Irf5−/− mice, though, data presented
in Figure 3G suggest a role for IRF5 in controlling IgG isotype
secretion; however, IgG2 and 4 levels were secreted at significantly lower levels than IgG1 and 3 in response to stimulation.
Additional work will be necessary to determine the role of IRF5
in human CSR.
The finding of reduced plasmablast differentiation in isolated naive B cells nucleofected with IRF5 siRNA highlights a
new B cell-intrinsic role for IRF5. These findings overlap with
recent work in a murine model of lupus showing reduced ASCs
in Irf5−/− MRL/lpr mice (20). However, it was not determined
whether reduced ASCs was a result of IRF5 B cell-intrinsic or
-extrinsic function. Data presented herein also point to IRF5
influences on late stage B cell effector functions. This is supported
by the large difference in IgG isotype secretion as compared to
intracellular IgG suggesting a potential role for IRF5 in secretion
(Figures 3D–F).
Interferon regulatory factor 5 activity/function following
nuclear translocation can occur through either transcriptional
regulation or protein–protein interactions. We conclude from

Frontiers in Immunology | www.frontiersin.org

ChIP-Seq analysis that IRF5 regulates the transcriptional control
of ASC differentiation. Through ChIP-Seq analysis, we found
that IRF5 bound a wide range of target genes involved in proliferation, ASC differentiation, and cell cycle control. Among the
most prominent targets were ERK1, IRF4, and MYC. Previous
characterization of IRF5 transcriptional targets was in murine
macrophages, revealing that IRF5 and NFĸB bound promoters
of inflammatory cytokines (60). Earlier ChIP-Seq work in human
PBMC found IRF5 to have overlapping transcriptional targets
with STAT4 (70). Results presented herein represent the first
characterization of IRF5 target genes in human primary B cells.
In stark contrast to previous work, IRF5 regulated pathways in
human B cells are focused on proliferation, survival, cell cycle, and
ASC differentiation (Figures 6 and 7; Figure S5 in Supplementary
Material).
Results from RNA-Seq further confirm an intrinsic role for
IRF5 in ASC differentiation. Genes known to be critical in B cell
proliferation and differentiation were drastically reduced following knockdown (Figure 5F). Our finding of decreased PRDM1
expression was similar to previous work in Irf5−/− mice carrying mutant DOCK2 (25, 26); however, we did not detect direct
binding of IRF5 to the PRDM1 promoter even though ISRE
and IRF-E sites were identified (Table 3). Rather, data indicate
that decreased PRDM1 expression is a byproduct of other genes
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regulated by IRF5, such as ERK1 and MYC (8, 62). It is intriguing
to propose from these data that IRF5 may be a gatekeeper for
antigen-stimulated naive B cells to enter the proliferation cycle.
If true, then alterations in IRF5 activation during early stages
of B cell activation may initiate the first break in self-tolerance.
Current limitations in manipulating primary B cells, however, did
not allow us to address whether the defect in B cell proliferation
was due to reduced proliferation potential or reduced numbers of
cells entering the cell cycle (Figures 3A,B). However, these data
provide insight into other aspects of IRF5 function. For instance,
the observed decrease in B cell proliferation suggests that the
significant increase in IgD+ B cells detected after IRF5 knockdown is due to retention of IgD+ B cells rather than increased de
novo synthesis since this would have been detected as an increase
in proliferation rather than a decrease. Further, it implies that
sufficient cell numbers were present for entering the cell cycle in
response to BCR/TLR9 signaling. Instead, findings from pathway
analysis of ChIP-Seq and RNA-Seq datasets support a key role for
IRF5 in B cell proliferation via cell cycle regulation (Figure 7).
Unfortunately, we were also unable to determine whether overexpression of MYC could restore ASC differentiation in IRF5
knockdown cells due to limitiations in transfection and/or viral
infection efficiency (54, 55, 71). Complementary experiments
in mice or CRISPR/Cas9 in primary naive B cells (72) will be
required to further elucidate the mechanisms by which IRF5
controls early stages of ASC differentiation.
Last, results presented herein have direct implications for
IRF5 function in SLE B cells. SLE patients carrying IRF5 risk
polymorphisms show elevated IRF5 expression in B lymphoblastoid cell lines (15, 16). SLE patients have elevated numbers
of circulating ASCs that contribute to pathogenic autoantibody
production and elevated circulating autoantibodies are present
years before clinical symptoms (2, 4). It is intriguing to propose
that polymorphisms in IRF5 contribute to early skewing of B cell
subset distribution and to breaks in self-tolerance which may
ultimately lead to the observed increase in circulating ASCs and
autoantibodies found in SLE patients.
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